Exploring Integrin α5β1 as a Potential Therapeutic Target for Pulmonary Arterial Hypertension: Insights From Comprehensive Multicenter Preclinical Studies
Circulation · 22.04.2025 · 151 (16) · 1162-1183
DOI: 10.1161/circulationaha.124.070693 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Circulation, erschienen am 22.04.2025. Verfasst von Sarah-Eve Lemay und 29 weiteren Autor:innen. Beteiligte Einrichtung: Pulmonary Hypertension Research Group, Québec Heart and Lung Institute Research Center, Quebec City, QC, Canada (S.-E.L., Y.G., T.Y., T.S., M.M., C.R…. Hauptthemen laut MEDLINE: Integrin alpha5beta1, Pulmonary Arterial Hypertension, Pulmonary Artery. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHLBI NIH HHS.
Abstract (Originalsprache)
BACKGROUND: Pulmonary arterial hypertension (PAH) is characterized by obliterative vascular remodeling of the small pulmonary arteries (PAs) and progressive increase in pulmonary vascular resistance leading to right ventricular failure. Although several drugs are approved for the treatment of PAH, mortality rates remain high. Accumulating evidence supports a pathological function of integrins in vessel remodeling, which are gaining renewed interest as drug targets. However, their role in PAH remains largely unexplored. METHODS: The expression of the RGD (arginylglycylaspartic acid)–binding integrin α5β1 was assessed in PAs, PA smooth muscle cells, and PA endothelial cells from patients with PAH and controls using NanoString, immunoblotting, and Mesoscale Discovery assays. RNA sequencing was conducted to identify gene networks regulated by α5β1 inhibition in PAH PA smooth muscle cells. The therapeutic efficacy of α5β1 inhibition was evaluated using a novel small molecule inhibitor and selective neutralizing antibodies in Sugen/hypoxia and monocrotaline rat models, with validation by an external contract research organization. Comparisons were made against standard-of-care therapies (ie, macitentan, tadalafil) and sotatercept and efficacy was assessed using echocardiographic, hemodynamic, and histological assessments. Ex vivo studies using human precision-cut lung slices were performed to further assess the effects of α5β1 inhibition on pulmonary vascular remodeling. RESULTS: We found that the arginine-glycine-aspartate RGD-binding integrin α5β1 is upregulated in PA endothelial cells and PA smooth muscle cells from patients with PAH and remodeled PAs from animal models. Blockade of the integrin α5β1 or depletion of the α5 subunit downregulated FOXM1 (forkhead box protein M1)–regulated gene networks, resulting in mitotic defects and inhibition of the pro-proliferative and apoptosis-resistant phenotype of PAH cells. We demonstrated that α5β1 integrin blockade safely attenuates pulmonary vascular remodeling and improves hemodynamics and right ventricular function and matched or exceeded the efficacy of standard of care and sotatercept in multiple preclinical models. Ex vivo studies further validated its potential in reversing advanced remodeling in human precision-cut lung slices. CONCLUSIONS: These findings establish α5β1 integrin as a pivotal driver of PAH pathology and we propose its inhibition as a novel, safe, and effective therapeutic strategy for PAH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pulmonary Hypertension Research Group, Québec Heart and Lung Institute Research Center, Quebec City, QC, Canada (S.-E.L., Y.G., T.Y., T.S., M.M., C.R., M.S., S.B.-B., A.B., C.T., A.P., R.E.K., S.M., K.Y., F.P., S.P., O.…
- Morphic Therapeutic, Inc, Waltham, MA (M.S.M., M.A., A.S.R., B.L., B.G., F.-Y.L., H.W., J.E.D., M.L., Q.Q., T.A.M., T.I.M.).
- Department of Cardiovascular Medicine, Fukushima Medical University, Japan (T.Y.).
- Department of Anesthesiology, St Mary's Hospital, Kurume, Fukuoka, Japan (T.S.).
- Department of Medicine, Laval University, Quebec City, QC, Canada (F.P., S.P., O.B., S.B.).
ORCID-Profile: Sarah-Eve Lemay, Yann Grobs, Tetsuro Yokokawa, Tsukasa Shimauchi, Charlotte Romanet, Sandra Martineau, Adrian S Ray, Qi Qiao, Steeve Provencher, Olivier Boucherat, Sébastien Bonnet
Förderung
- NHLBI NIH HHS
Zitieren
APA
Lemay, S. E., Montesinos, M. S., Grobs, Y., Yokokawa, T., Shimauchi, T., Mougin, M., Romanet, C., Sauvaget, M., Breuils-Bonnet, S., Bourgeois, A., Théberge, C., Pelletier, A., El Kabbout, R., Martineau, S., Yamamoto, K., Akram, M., Ray, A. S., Lippa, B., Goodwin, B., …, & Bonnet, S. (2025). Exploring Integrin α5β1 as a Potential Therapeutic Target for Pulmonary Arterial Hypertension: Insights From Comprehensive Multicenter Preclinical Studies. Circulation, 151(16), 1162-1183. https://doi.org/10.1161/circulationaha.124.070693
Vancouver
Lemay SE, Montesinos MS, Grobs Y, Yokokawa T, Shimauchi T, Mougin M, et al. Exploring Integrin α5β1 as a Potential Therapeutic Target for Pulmonary Arterial Hypertension: Insights From Comprehensive Multicenter Preclinical Studies. Circulation. 2025;151(16):1162-1183. doi:10.1161/circulationaha.124.070693
BibTeX
@article{Lemay2025,
author = {Lemay, Sarah-Eve and Montesinos, Mónica S and Grobs, Yann and Yokokawa, Tetsuro and Shimauchi, Tsukasa and Mougin, Manon and Romanet, Charlotte and Sauvaget, Mélanie and Breuils-Bonnet, Sandra and Bourgeois, Alice and Théberge, Charlie and Pelletier, Andréanne and El Kabbout, Reem and Martineau, Sandra and Yamamoto, Keiko and Akram, Muzaffar and Ray, Adrian S and Lippa, Blaise and Goodwin, Bryan and Lin, Fu-Yang and Wang, Hua and Dowling, James E and Lu, Min and Qiao, Qi and McTeague, T Andrew and Moy, Terence I and Potus, François and Provencher, Steeve and Boucherat, Olivier and Bonnet, Sébastien},
title = {Exploring Integrin α5β1 as a Potential Therapeutic Target for Pulmonary Arterial Hypertension: Insights From Comprehensive Multicenter Preclinical Studies},
journal = {Circulation},
year = {2025},
volume = {151},
number = {16},
pages = {1162--1183},
doi = {10.1161/circulationaha.124.070693}
}
EUVIMED